Liver Cancer Treatment Market Size, Share & Industry Analysis, By Treatment Type (Chemotherapy, Immunotherapy, Targeted Drug Therapy, Radiation Therapy, Others), By End User (Hospitals, Specialty Clinics, Research Laboratories, Others) Others and Regional Forecast, 2024-2032

Liver cancer is a condition or disease that occurs when normal cells in the liver become abnormal in appearance and behavior. The cancer cells then become destructive to adjacent normal tissues, and can spread both to other areas of the liver and to organs outside the liver. Liver cancer is also known as hepatic cancer. The major cause of liver cancer is chronic liver disease, cirrhosis which scars the liver and thus increases the risk of liver cancer. Other causes of liver cancer are linked to environmental, dietary, or lifestyle factors. The symptoms of liver cancer do not usually become apparent until the disease reaches an advanced stage. The symptoms generally include jaundice, abdominal pain, unexplained weight loss, an enlarged liver, spleen, or both, fatigue, back pain, itching, and fever.

Treatments for primary liver cancer depend on the extent (stage) of the disease as well as on age, overall health and personal preferences. The primary treatment options include surgery, chemotherapy, radiation therapy, immunotherapy, targeted drug therapy and palliative care.

Factors such as rising prevalence of liver cancer, growing research activities for developing novel treatments and increased government funding for the cancer treatment research are driving the growth of global liver cancer treatment market. According to World Cancer Research Fund International, liver cancer is the fifth most commonly occurring cancer in men and ninth most commonly occurring cancer in women and there were about 840,000 new liver cancer cases in 2018, globally.

However, high research and development cost, stringent drug approval process and adverse side effects associated with cancer treatment medications, are projected to hamper the market growth.

Market Segmentation:

By treatment, the market is segmented into chemotherapy, immunotherapy, targeted therapy, radiation therapy and others. Based on end users, the market is segmented into hospitals, specialty clinics, research laboratories and others.

By geographic standpoint, the liver cancer treatment market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.

Key Players Covered:

Some of the major companies that are present in the liver cancer treatment market are F. Hoffmann-La Roche Ltd, Abbott, Sysmex Corporation, Siemens Healthcare GmbH, Danaher, Thermo Fisher Scientific Inc., and other prominent players

Key Insights

• Prevalence of Liver Cancer for Key Countries/Regions, 2018


• New Product Launches in Liver Cancer Treatment Market


• Technological Advancements in Global Liver Cancer Treatment Market


• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions

Regional Analysis:

North America is projected to dominate the global liver cancer treatment market over the forecast period, followed by Europe. The dominance of this region is mainly attributed to the factors such as presence of a large patient population, demand for care diagnostics, improved technology, and quick adoption of novel therapeutics and diagnostic approaches

On the other hand, Asia Pacific is expected to witness the fastest growth during the forecast period. Presence of well-established hospitals and critical care centers, expanded interest for developing novel treatment options as well as large population suffering from liver cancer drive the growth of the market in Asia Pacific region. Latin America and Middle East America are also expected to have a substantial growth in the liver cancer treatment market.

Segmentation

Liver Cancer Treatment Industry Developments

• In August 2019, immunology researcher at the Roswell Park Comprehensive Cancer Centre launched a biomarker that explains patients’ response to a common chemotherapy for liver cancer.


• In November 2018, Eisai China Inc., a Chinese subsidiary of Eisai Co., Ltd. launched the kinase inhibitor LENVIMA which is the first new systemic therapy for the first-line treatment of hepatocellular carcinoma in China.


• In April 2017, the U.S. Food and Drug Administration granted the approval of STIVARGA (Regorafenib) to Bayer HealthCare Pharmaceuticals Inc. to include the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.